Uterine Carcinosarcoma in A BRCA2 Mutation Carrier

Petersen SS, Quigg MH, Zhang Z and Buekers T

Department of Women's Health Services, Henry Ford Hospital, USA
Department of Medical Genetics, Henry Ford Hospital, USA
Department of Pathology, Henry Ford Hospital, USA
Division of Gynecology Oncology, Department of Women's Health Services, Henry Ford Hospital, USA

^*Correspondance to: Thomas E. Buekers 

 PDF  Full Text Case Report | Open Access

Abstract:

Background: Uterine carcinosarcoma is one of the most aggressive uterine cancers, with 5-year survival for advanced stage disease of 30%. Currently, there is no optimal standard chemotherapy regimen for uterine carcinosarcoma and most patients suffer from disease recurrence.Case
Presentation: A 68 year-old Ashkenazi Jewish woman was diagnosed with stage IIIC2 uterine carcinosarcoma after presenting with abdominal pain. Although uterine carcinosarcoma is not currently associated with any genetic syndrome, her ancestry and family history of breast cancer prompted genetic screening. She was found to be a carrier of the BRCA2 mutation. After surgical resection and chemotherapy with carboplatin/paclitaxel, she had complete response and has had disease free survival for over 23 months.Conclusion: We report prolonged disease free survival of uterine carcinosarcoma in BRCA2 mutation carrier.

Keywords:

Cite the Article:

Petersen SS, Quigg MH, Zhang Z, Buekers T. Uterine Carcinosarcoma in A BRCA2 Mutation Carrier. Clin Oncol. 2016; 1: 1111.